Therapeutic potential of furin inhibitors for the chronic infection of hepatitis B virus

Liver International

Volumn 33, Issue 8, 2013, Pages 1230-1238

  Pang, Yan J ^a   Tan, Xiao J ^a   Li, Dong M ^a   Zheng, Zi H ^a   Lei, Rui X ^a   Peng, Xiao M ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b Liver Disease Key Laboratory of Guangdong Province   (China)

Author keywords

Chronic hepatitis B; Furin; Hepatitis B e antigen; Hepatitis B virus; Maturation; Proprotein convertase; Protease inhibitor

Indexed keywords

ALBUMIN; DECANOYL RVKR CHLOROMETHYLKETONE; FURIN; HEPATITIS B(E) ANTIGEN; HEXA D ARGININE; PROTHROMBIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DAMAGE; CELL STRAIN HEPG2; CELL SURFACE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOSOL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; PRECURSOR; SECRETION (PROCESS); SUPERNATANT; VIRUS REPLICATION;

CHRONIC HEPATITIS B; FURIN; HEPATITIS B E ANTIGEN; HEPATITIS B VIRUS; MATURATION; PROPROTEIN CONVERTASE; PROTEASE INHIBITOR;

AMINO ACID CHLOROMETHYL KETONES; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FURIN; HEP G2 CELLS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TRANSPORT; PROTHROMBIN; SERUM ALBUMIN; TRANSFECTION;

EID: 84881499581     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12185     Document Type: Article

References (33)

1. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010; 51: 435-44.
2. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
3. Liaw YF. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment. Liver Int 2009; 29(Suppl. 1): 100-7.
4. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24.
5. Leung N. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues. Liver Int 2011; 31(Suppl. 1): 85-9.
6. Messageot F, Salhi S, Eon P, Rossignol JM. Proteolytic processing of the hepatitis B virus e antigen precursor. Cleavage at two furin consensus sequences. J Biol Chem 2003; 278: 891-5.
7. Ito K, Kim KH, Lok AS, Tong S. Characterization of genotype-specific carboxyl-terminal cleavage sites of hepatitis B virus e antigen precursor and identification of furin as the candidate enzyme. J Virol 2009; 83: 3507-17.
8. Schlicht HJ, Schaller H. The secretory core protein of human hepatitis B virus is expressed on the cell surface. J Virol 1989; 63: 5399-404.
9. Duriez M, Rossignol JM, Sitterlin D. The hepatitis B virus precore protein is retrotransported from endoplasmic reticulum (ER) to cytosol through the ER-associated degradation pathway. J Biol Chem 2008; 283: 32352-60.
10. Milich DR, Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160: 2013-21.
11. Chen MT, Billaud JN, Sällberg M, et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A 2004; 101: 14913-8.
12. Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol 1997; 71: 345-53.
13. Frelin L, Wahlström T, Tucker AE, et al. A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection. J Virol 2009; 83: 1379-92.
14. Lei RX, Shi H, Peng XM, et al. Influence of a single nucleotide polymorphism in the P1 promoter of the furin gene on transcription activity and hepatitis B virus infection. Hepatology 2009; 50: 763-71.
15. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002; 3: 753-66.
16. Becker GL, Lu Y, Hardes K, et al. Highly potent inhibitors of the proprotein convertase furin as potential drugs for the treatment of infectious diseases. J Biol Chem 2012; 287: 21992-2003.
17. Cameron A, Appel J, Houghten RA, Lindberg I. Polyarginines are potent furin inhibitors. J Biol Chem 2000; 275: 36741-9.
18. Wu JF, Hsu HY, Ni YH, et al. Suppression of furin by interferon-γ and the impact on hepatitis B virus antigen biosynthesis in human hepatocytes. Am J Pathol 2012; 181: 19-25.
19. Sugiyama M, Tanaka Y, Kurbanov F, et al. Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene. Virology 2007; 365: 285-91.
20. Sarac MS, Peinado JR, Leppla SH, Lindberg I. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. Infect Immun 2004; 72: 602-5.
21. Sarac MS, Cameron A, Lindberg I. The furin inhibitor hexa-D-arginine blocks the activation of Pseudomonas aeruginosa exotoxin A in vivo. Infect Immun 2002; 70: 7136-9.
22. Biermer M, Puro R, Schneider RJ. Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol 2003; 77: 4033-42.
23. Seifer M, Standring DN. A protease-sensitive hinge linking the two domains of the hepatitis B virus core protein is exposed on the viral capsid surface. J Virol 1994; 68: 5548-55.
24. Wallin R, Stanton C, Hutson SM. Intracellular maturation of the gamma-carboxyglutamic acid (Gla) region in prothrombin coincides with release of the propeptide. Biochem J 1993; 291: 723-7.
25. Misumi Y, Oda K, Fujiwara T, et al. Functional expression of furin demonstrating its intracellular localization and endoprotease activity for processing of proalbumin and complement pro-C3. J Biol Chem 1991; 266: 16954-9.
26. Mori K, Imamaki A, Nagata K, et al. Subtilisin-like proprotein convertases, PACE4 and PC8, as well as furin, are endogenous proalbumin convertases in HepG2 cells. J Biochem 1999; 125: 627-33.
27. Peinado JR, Kacprzak MM, Leppla SH, Lindberg I. Cross-inhibition between furin and lethal factor inhibitors. Biochem Biophys Res Commun 2004; 321: 601-5.
28. Messageot F, Carlier D, Rossignol JM. The C terminus of the hepatitis B virus e antigen precursor is required for a tunicamycin-sensitive step that promotes efficient secretion of the antigen. J Biol Chem 1998; 273: 18594-8.
29. Pesu M, Watford WT, Wei L, et al. T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature 2008; 455: 246-50.
30. Roebroek AJ, Taylor NA, Louagie E, et al. Limited redundancy of the proprotein convertase furin in mouse liver. J Biol Chem 2004; 279: 53442-50.
31. Becker GL, Sielaff F, Than ME, et al. Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem 2010; 53: 1067-75.
32. Seol DW. p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun 2011; 416: 222-5.
33. Fiume L, Di Stefano G. Lactosaminated human albumin, a hepatotropic carrier of drugs. Eur J Pharm Sci 2010; 40: 253-62.